Navigation Links
Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Date:9/12/2007

SOMERSET, N.J., Sept. 12 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced it has confirmed that 290 evaluable events (patient deaths) have occurred in the Phase IIIb clinical trial of its lead compound, ONCONASE, for the treatment of patients with unresectable malignant mesothelioma. The number of evaluable events was confirmed after the company learned that total events in the study had reached 316. In accordance with the statistical plan for the study, the company must wait until 316 evaluable events have occurred to conduct the formal statistical analysis required to complete the ONCONASE New Drug Application (NDA). Enrollment in the ONCONASE Phase IIIb clinical trial is scheduled to close on Sept. 30, 2007. To date, a total of 425 patients have been enrolled in the trial.

To be considered evaluable, patients must meet all of the eligibility requirements for the study and receive at least one dose of study drug. Alfacell projects that 316 evaluable events will occur before the end of 2007. Upon reaching this milestone, the company expects to proceed using the following schedule to provide updates regarding the potential completion of the final sections of its ONCONASE rolling NDA submission:

-- Report occurrence of 316 evaluable events via news release within 72

hours of confirmation by Alfacell

-- If data are positive, submit final clinical section of rolling NDA

within four months of reporting 316 evaluable events and announce

submission via news release

Alfacell estimates that it has sufficient cash resources available to continue to fund the completion of the ONCONASE Phase III program and the rolling NDA submission.

In additi
'/>"/>

SOURCE Alfacell Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
3. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
4. Researchers Identify Intracellular Pathway of Alfacells Onconase
5. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
6. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
7. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
10. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
11. NCCN Updates Esophageal and Gastric Cancer Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014 ... the U.S. commercial launch of its foot plating system ... Paragon 28.  The GORILLA TM R3CON PLATING SYSTEM ... the Monster TM & Mini-Monster TM Screw ... Comprised of 10 interchangeable subsystems, the GORILLA TM ...
(Date:9/22/2014)... Research and Markets ( ... the  "Global Remotes Market 2014-2018"  report to ... Remotes/remote controls are devices that ... such as smart TVs, set top boxes, ... distance. Remote controls are small wireless handheld ...
(Date:9/22/2014)... -- Final shortlist announced, winners to ... The second edition of the much-awaited VCCircle Healthcare Awards is round ... final nominations for the 2014 honours.  The names of ... 25 at The Taj Mahal Palace, Mumbai . The ... variety of qualitative and quantitative parameters - such as ...
Breaking Medicine Technology:Paragon 28, Inc. Launches the GORILLA(TM) R3CON PLATING SYSTEM 2Global Remotes Market 2014-2018 2Global Remotes Market 2014-2018 3Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3
... LYON, France, May 11, 2012 Mylan Inc. (Nasdaq: ... launched Atorvastatin Calcium Tablets, 10 mg, 20 mg, 40 ... the Netherlands and Ireland. Mylan has received marketing authorization ... its product immediately. Atorvastatin Calcium is the generic version ...
... /PRNewswire-iReach/ -- Electrochemical Oxygen Concepts (EO2™ ... chronic wound treatment device, announced it has been ... Federal Supply Schedule (FSS) contract, administered by The ... ® , a noninvasive, electrochemical low-dose tissue oxygenation ...
Cached Medicine Technology:Mylan Launches Generic Lipitor® in Five European Countries 2New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program 2New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program 3
(Date:9/22/2014)... (PRWEB) September 22, 2014 Airbus Helicopters ... industry Monday for their efforts to improve safety and ... Award and the Program of the Year award, both ... Air Medical Transport Conference Annual Community Awards. , ... with the Jim Charlson Aviation Safety Award, given annually ...
(Date:9/22/2014)... September 22, 2014 Starbrite Dental ... patients who require orthodontic work. Six-Month Smiles is designed ... deserve in a fast and effective way. , Many ... extremely daunting. Having to wear metal braces for several ... and spend time keeping the braces clean, is undesirable ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 United ... all of the federal mesh lawsuits ( http://www.meshinjurylawfirm.com/lawsuits/ ... have been consolidated for pretrial matters, issued an ... Corp. Pelvic Repair System Products Liability Litigation (United ... West Virginia; Case no. 2:12-md-02326)—requiring that four member ...
(Date:9/22/2014)... more and drink more , Study used smartphones to ... differ from past research on physical activity and exercise ... that on days when people exercise more -- typically ... , This is the only study to use smartphone ... activity and alcohol use. , "Monday through Wednesday people ...
(Date:9/22/2014)... and young adults at risk for sexually transmitted infections ... sexual behaviors, according to new recommendations from the U.S. ... million new sexually transmitted infections such as gonorrhea and ... people between 15 and 24 years old, according to ... Sept. 22 in Annals of Internal Medicine , ...
Breaking Medicine News(10 mins):Health News:Airbus Helicopters Inc. Honors Leaders in Air Medical Industry 2Health News:Airbus Helicopters Inc. Honors Leaders in Air Medical Industry 3Health News:Starbrite Dental Introduces Six-Month Smiles 2Health News:Federal Court Sets Trial Date for Boston Scientific Vaginal Mesh Cases in Florida, the Rottenstein Law Group LLP Reports 2Health News:We drink more alcohol on gym days 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 3
... statement,is being released by Sr. Carol Keehan, DC, ... Association of the United States (CHA):, The ... provided,today by the Holy See,s Congregation for the ... administered nutrition and,hydration to patients in a persistent ...
... Pharmaceuticals,Inc. (Nasdaq: AMLN ) management will be presenting ... Annual Meeting of the European,Association for the Study of ... PT / 1:30 p.m. CET local time in Amsterdam, ... recordings will be made,available following the event. The webcast ...
... Sept. 13 (HealthDay News) -- It,s under your movie seat ... , But relief may be in sight. This week, researchers ... chewing gum at the BA Festival of Science in York, ... clothes, hair and sidewalks, and preliminary tests indicate that it ...
... Mich., Sept. 14 Stryker,Corporation (NYSE: SYK ) ... conference: September 25, 2007 - 4:30 p.m. Eastern ... York, New York A simultaneous webcast of the ... http://www.stryker.com via the For Investors page. The,presentation for ...
... Sept. 14 Mylan Laboratories Inc.,(NYSE: MYL ... Lacerca to the,position of Senior Vice President and ... from Bristol-Meyers Squibb where she was,Director of Compliance ... she was responsible for all compliance-related matters in ...
... WASHINGTON, Sept. 14 - The successful,implementation of electronic ... program $1.2 million per month according to a ... and increased quality,demonstrated in Mississippi reinforces the importance ... Management Association,(PCMA) said today., "The state of ...
Cached Medicine News:Health News:Comment Regarding Congregation for the Doctrine of Faith Clarification Concerning Nutrition and Hydration for Patients in a Persistent Vegetative State 2Health News:Stryker to Present at Investor Conference 2Health News:Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer 2Health News:E-Prescribing Saving Mississippi Medicaid $1.2 Million Per Month 2
... Graham-Field has been developing diverse ... 58 years. Our medical-surgical products ... for innovation, quality and customer ... include the Labtron® line of ...
... spill-proof design and effective output, even when ... medical nebulizers are free-standing for easy preparation., ... available., ,All Portex® medication nebulizer products ... feature consistently fine misting and the efficient ...
... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
... with metered dose inhalers., ,ACE ensures ... MDI canisters. Its versatile design allows it ... in conjunction with an endotracheal airway or ... ACE may also be used in conjunction ...
Medicine Products: